NCT01248065

Phase 3Interventional

Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.

View on ClinicalTrials.gov ↗

Timeline

Start date: Apr 1, 2011
Primary completion: Jan 1, 2014
Completion date: Jan 1, 2014
First posted: —
Last posted: —
Enrollment: 408
Arms / groups: 2 / —
Source: AACT · pre-existing

Sponsors

Pennsylvania State UniversityLead sponsor
Duke UniversityOverall official - principal investigator
University of ChicagoOverall official - principal investigator
University of PittsburghOverall official - principal investigator
University of California, San FranciscoOverall official - principal investigator
Emory UniversityOverall official - principal investigator
Northwestern UniversityOverall official - principal investigator
Rush UniversityOverall official - principal investigator
University of WisconsinOverall official - principal investigator
North Carolina Clinical ResearchOverall official - principal investigator
Pennsylvania State UniversityOverall official - principal investigator
Case Western Reserve UniversityOverall official - principal investigator
University of VirginiaOverall official - principal investigator
Wake Forest UniversityOverall official - principal investigator
National Heart, Lung, and Blood Institute (NHLBI)Collaborator
Harvard UniversityOverall official - principal investigator
Washington University in St. LouisOverall official - principal investigator
Pennsylvania State UniversityReponsible party - principal investigator
University of Illinois at ChicagoOverall official - principal investigator
University of Colorado, DenverOverall official - principal investigator

Drugs studied

Indications studied

Asthma

CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.